StockData
TECHNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends June 30

BIO-TECHNE Corp

Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Aug 24, 2026
$72.49−0.08 (-0.11%)

Close on Oct 19, 2026

Market cap
$11.40B
P/E (TTM)
62.5
Dividend yield
0.44%

About Bio-Techne

Biological Products, (No Diagnostic Substances), SIC 2836

Bio-Techne Corporation develops, manufactures, and sells life science reagents, instruments, and analytical services across research, diagnostic, and bioprocessing markets. Operating through its Protein Sciences and Diagnostics and Spatial Biology segments, the company offers specialized proteins, antibodies, small molecules, manual and automated protein analysis tools, spatial genomic assays, and clinical diagnostic controls and calibrators. Its products serve academic and industrial researchers, pharmaceutical and biotechnology companies, contract research organizations, diagnostic developers, and clinical testing laboratories worldwide.

Headquartered in Minneapolis, Minnesota, the company operates globally with offices throughout North America, Europe, and Asia. Bio-Techne employs approximately 3,000 people and manufactures the majority of its portfolio across multiple locations in North America, as well as sites in the United Kingdom, Canada, Switzerland, and China.

Summary of the business section of Bio-Techne's latest annual report, written by StockData.

Company profile

Company

Legal name
BIO-TECHNE Corp
Founded
1976
Headquarters
Minneapolis, MN
Address
614 Mckinley Place Ne
Phone
(612) 379-8854
Employees
3,000, Jun 30, 2026
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Minnesota
Fiscal year ends
June 30
Auditor
KPMG LLP, Minneapolis, Minnesota

Stock & identifiers

Ticker
TECH
Exchange
Nasdaq
Shares outstanding
157M, Aug 17, 2026
Public float
$9.10B, Dec 31, 2025
Filer category
Large accelerated filer
Stock splits
4-for-1, Nov 30, 2022; 4-for-1, Nov 29, 2022; 2-for-1, Dec 4, 2000; 2-for-1, Nov 18, 1997
SEC CIK
842023
CUSIP
09073M104
ISIN
US09073M1045
LEI
54930073RLKQ51TILZ35
EIN
41-1427402

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Kim KeldermanChief Executive Officer, Director82,762
James HippelCFO170,183
Shane BohnenSVP - General Counsel10,360
William GeistPRESIDENT, PROTEIN SCIENCES24,943
Steven C. CrousePresident - Diag & Spatial Bi10,237
Matthew McManusPresident - Diag & Spatial Bio7,691
John L. HigginsDirector77,254
Robert V. BaumgartnerDirector56,884
Amy E. HerrDirector3,256
Rupert VesseyDirector10,987
Julie L. BushmanDirector8,775
Judith V. KlimovskyDirector3,782
Joseph D. KeeganDirector15,411
Alpna SethDirector15,411
Roeland NusseDirector44,559

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025
Keldeman
–$2.47M$3.75M$79$104
FY2025
Kelderman
$8.15M$2.47M$3.75M$79$104
FY2025
Kummeth
$0$0$3.75M$79$104
FY2024
Keldeman
–$2.83M$3.30M$110$131
FY2024
Kelderman
$2.64M$2.83M$3.30M$110$131
FY2024
Kemmeth
–$4.82M$3.30M$110$131

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Employees

Headcount reported in annual reports

“Through its subsidiaries, Bio-Techne employed approximately 3,000 full-time and part-time employees as of June 30, 2026, of whom approximately 2,200 were employed in the U.S.”

Corporate history

Events identified from SEC filings

DateEventDetails
Aug 20, 2026Merger voteDefinitive merger proxy statement
Aug 2, 2018Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Aug 29, 2017Late filingNotification of late filing
Oct 14, 2016Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Aug 2, 2016Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Oct 28, 2014Name changeName changed from TECHNE CORP /MN/ to BIO-TECHNE Corp
Oct 16, 2014Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Aug 1, 2014Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jul 8, 2011Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
May 4, 2011Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Nov 10, 2004Late filingNotification of late filing